<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomed Res Int</journal-id><journal-id journal-id-type="iso-abbrev">Biomed Res Int</journal-id><journal-id journal-id-type="publisher-id">BMRI</journal-id><journal-title-group><journal-title>BioMed Research International</journal-title></journal-title-group><issn pub-type="ppub">2314-6133</issn><issn pub-type="epub">2314-6141</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7688356</article-id><article-id pub-id-type="doi">10.1155/2020/8872479</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Antioxidant Activity of Telmisartan&#x02013;Cu(II) Nanoparticles Connected 2-Pyrimidinamine and Their Evaluation of Cytotoxicity Activities</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Surendrakumar</surname><given-names>Radhakrishnan</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0309-6274</contrib-id><name><surname>Idhayadhulla</surname><given-names>Akbar</given-names></name><email>a.idhayadhulla@gmail.com</email><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Alarifi</surname><given-names>Saud</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ahamed</surname><given-names>Nazeer Anis</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sathish Kumar</surname><given-names>Chidambaram</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Research Department of Chemistry, Nehru Memorial College (Affiliated to Bharathidasan University), Puthanampatti, Tiruchirappalli District, 621007 Tamil Nadu, South India, India</aff><aff id="I2">
<sup>2</sup>Department of Zoology, College of Sciences, King Saud University (KSU), P.O. Box 2455, Riyadh 11451, Saudi Arabia</aff><aff id="I3">
<sup>3</sup>Department of Botany &#x00026; Microbiology, College of Sciences, King Saud University (KSU), Riyadh, Saudi Arabia</aff><author-notes><fn fn-type="other"><p>Academic Editor: Hui-Min David Wang</p></fn></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>18</day><month>11</month><year>2020</year></pub-date><volume>2020</volume><elocation-id>8872479</elocation-id><history><date date-type="received"><day>3</day><month>9</month><year>2020</year></date><date date-type="rev-recd"><day>15</day><month>9</month><year>2020</year></date><date date-type="accepted"><day>30</day><month>10</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Radhakrishnan Surendrakumar et al.</copyright-statement><copyright-year>2020</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Copper nanoparticles (Cu-Nps) are one of the promising materials for the advancement of nanoscience and technology. In this work, we synthesized telmisartan copper nanoparticles and 2-pyrimidinamines via Biginelli reaction using telmisartan copper nanoparticles (Cu-Nps) as a reusable catalyst. The synthesis of 2-pyrimidinamine derivatives (1a-c) was achieved in water and under solvent-free condition (Green chemistry approach). Synthesis of 2-pyrimidinamine with telmisartan copper nanoparticle (Cu-Nps&#x02013;Pyr) unexpected product was also isolated from synthesis of 2-pyrimidinamine preparation. Antioxidant and cytotoxic activities were carried out both in 2-pyrimidinamine (1a-1c) and 2-pyrimidinamine with telmisartan copper nanoparticles (Cu-Nps&#x02013;Pyr). The synthesized 2-pyrimidinamine derivatives (1a-c) were characterized from FT-IR, <sup>1</sup>H and <sup>13</sup>C NMR spectroscopy, mass and elemental analyses. The synthesized telmisartan copper nanoparticles (Cu-Nps) were characterized from UV spectroscopy, XRD, SEM, EDX, AFM (atomic force microscopy), profile, waviness, and roughness analyses. Antioxidant activity was screened based on ABTS<sup>&#x000b7;+</sup> radical scavenging and linoleic acid peroxidation performance. Cu-Nps&#x02013;Pyr-1b showed substantial antioxidant (97.2%) activity against ABTS<sup>&#x000b7;+</sup> assay and 91.2% activity against AAPH assays compared with Trolox. Cytotoxicity was evaluated using HepG2, HeLa, and MCF-7 cell lines, the Cu-Nps&#x02013;Pyr-1a is high in toxicities (GI<sub>50</sub> = 0.01&#x02009;<italic>&#x003bc;</italic>m) against the HeLa cancel cell line compared with doxorubicin. The developed copper NPs with 2-pyrimidinamine (Cu-Nps&#x02013;Pyr) could provide promising advances as antioxidant activities; this nanocomposition could be considered an anticancer treatment in future investigations.</p></abstract><funding-group><award-group><funding-source>King Saud University</funding-source><award-id>RSP-2020/27</award-id></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Pyrimidinamine has great importance as it is widely spread in living organisms and also a broad spectrum of biological activities such as antitumor properties [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>], herbicidal [<xref rid="B3" ref-type="bibr">3</xref>], fungicidal [<xref rid="B4" ref-type="bibr">4</xref>], antidepressant [<xref rid="B5" ref-type="bibr">5</xref>], and also, amino pyrimidine was an indicator of antitumor [<xref rid="B6" ref-type="bibr">6</xref>], antibacterial [<xref rid="B7" ref-type="bibr">7</xref>], and antiviral [<xref rid="B8" ref-type="bibr">8</xref>] activities. The biological importance of natural and synthetic 2-pyrimidinamine core derivatives are shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>, such as alkaloidal (divicine) properties found in fava beans, the aglycone of vicine [<xref rid="B9" ref-type="bibr">9</xref>], the cytotoxic activity of alkaloid marine sponge (bromohymenialdisine) [<xref rid="B10" ref-type="bibr">10</xref>], and antifeedant of alkaloid (dibromoisophakellin) [<xref rid="B11" ref-type="bibr">11</xref>].</p><p>Telmisartan is used in the management of hypertension, which acts as an angiotensin II receptor blocker (ARB). The structure of telmisartan is shown in <xref ref-type="fig" rid="fig2">Figure 2</xref> and their orally active direct-acting AII, the AT1receptor antagonist potential of pharmacotherapy of hypertension [<xref rid="B12" ref-type="bibr">12</xref>].</p><p>Scavenging ROS antioxidants of acetyl cysteine additionally L-carnitine are observed to cure the inflammatory diseases [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>]. However, it does not performed well against ROS-related diseases due to poor bioavailability and various limitations of clinical screening [<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>]. Recently, studies reported that copper-based nanoparticles improved the ROS-related diseases and higher scavenging ability of this treatment [<xref rid="B17" ref-type="bibr">17</xref>]. Copper (Cu) is one of the best elements in recommendation for human usage, which play an important role in tyrosinase and Cu&#x02013;ZnSOD enzyme [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>]. Cu enzyme activity is basically a response to many bioactivities such as connective tissue biosynthesis, cellular respiration, neurotransmitter production, iron homeostasis, peptide biogenesis, pigment formation, and antioxidant defense [<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>]. Particularly, Cu-NPs has outstanding catalytic activity to scavenge H<sub>2</sub>O<sub>2</sub> and O<sub>2</sub> [<xref rid="B22" ref-type="bibr">22</xref>] but cannot eliminate OH&#x000b7; simultaneously [<xref rid="B23" ref-type="bibr">23</xref>] and also can promote electron transfer reactions to inactivate H<sub>2</sub>O<sub>2</sub> or OH&#x000b7; [<xref rid="B24" ref-type="bibr">24</xref>]. The catalytic behavior of Cu compounds in organic reaction motivated us to focus our attention on the application of our research. As a result, we assume that the capacity of Cu-Nps acts as catalytic as well as antioxidant activities simultaneously. In addition, the stability of Cu-NPs can be largely enhanced, which is also developing the overall ROS scavenging ability [<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>]. Based on the above observation, we designed to synthesize, high active 2-pyrimidinamine connected with Cu nanoparticles and evaluated the antioxidant of ABTS<sup>&#x000b7;+</sup>, linoleic acid peroxidation, and cytotoxic activities.</p></sec><sec id="sec2"><title>2. Material and Methods</title><sec id="sec2.1"><title>2.1. General Materials and Characterization Techniques</title><sec id="sec2.1.1"><title>2.1.1. Chemistry</title><p>Telmisartan-mediated copper nanoparticle was analyzed from UV, FT-IR, SEM, X-ray with EDX, and AFM methods. FT-IR is recorded via Shimadzu 8201pc (4000-400&#x02009;cm<sup>&#x02212;1</sup>). The <sup>1</sup>H and <sup>13</sup>C NMR were recorded via JEOL-300&#x02009;MHz. An elemental analyzer model (Varian EL III) was used for analysis of elemental presences. Thin layer chromatography was used for purity checking.</p></sec></sec><sec id="sec2.2"><title>2.2. Synthesis of Telmisartan-Mediated Copper Nanoparticles</title><p>The mixture of CuCl<sub>2</sub>&#x000b7;2H<sub>2</sub>O (0.5&#x02009;mmol, 5&#x02009;mL) and telmisartan (1&#x02009;mmol, 10&#x02009;mL) was added in ethanol; then, the reaction mixture was allowed 1&#x02009;M NaOH with stirring and maintained pH = 7. The reaction mixture converted blue precipitate followed by adding of water (15&#x02009;mL). The precipitate was obtained, then filtered all precipitate and purified with suitable techniques.</p></sec><sec id="sec2.3"><title>2.3. General Method for Preparation of 2-Pyrimidinamine Derivatives (1a-1c) via Biginelli Reaction</title><p>The compound urea (0.01&#x02009;mol, 0.6&#x02009;g), Cu catalyst (0.01&#x02009;mol, 1.7&#x02009;g), ethyl acetoacetate (0.01&#x02009;mol, 1.3&#x02009;mL), benzaldehyde (0.01&#x02009;mol, 1&#x02009;mL), and substituted amine (0.05&#x02009;mol, 1.6&#x02009;mL) are mixed well together in a mortar and two drops of the con. HCl were added. The precipitate was dissolved in ethanol. The undissolved catalyst was filtered and dried in vacuum and used for the next cycle. The final product was obtained from the evaporation of ethanol from the filtrate and unexpected product also obtained. The final compound was confirmed by TLC. The pure product was obtained from the using suitable recrystallized method. The above procedure was followed for synthesis of the remaining compounds 1b and 1c.</p></sec><sec id="sec2.4"><title>2.4. Recyclability of Cu-Np Catalyst</title><p>Investigation of recovery the catalyst and usage via washing and dried with ethanol by under vacuum condition are shown.</p><sec id="sec2.4.1"><title>2.4.1. Ethyl 2-hydrazono-6-methyl-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1a)</title><p>The composition of 1a is as follows: black solid; mw: 274.32; mp 136&#x000b0;C; IR (cm<sup>&#x02212;1</sup>): 3246.11 (NH), 3119.59 (Ph-CHstr), 3033.92 (Ar-H), 2597.00 (C=N), 1713.57 (OCOEt); <sup>1</sup>H NMR (300&#x02009;MHz, DMSO- d<sub>6</sub>): <italic>&#x003b4;</italic> 9.20 (2H, s, NH), 8.84 (2H, s, NH<sub>2</sub>), 7.33(2H, dd, <italic>J</italic> = 7.33Hz, <italic>J</italic> = 7.37&#x02009;Hz Ph), 7.28 (1H, d, <italic>J</italic> = 6.21&#x02009;Hz, phenyl), 7.23(2H, dd, <italic>J</italic> = 7.31&#x02009;Hz, <italic>J</italic> = 7.35&#x02009;Hz Ph), 4.20 (2H, m, -CH<sub>2</sub>) 4.16 (1H, d, <italic>J</italic> = 6.21&#x02009;Hz, -CH), 2.26 (3H, s, -CH<sub>3</sub>), 1.29 (3H, s, -CH<sub>3</sub>); <sup>13</sup>C NMR(300&#x02009;MHz, DMSO-d<sub>6</sub>): 167.2 (1C, <underline>C</underline>=O), 160.3(1C, -<underline>C</underline>-CH<sub>3</sub>), 154.0 (1C, C=N), 143.3, 128.5, 126.9, 126.7 (6C, Ar ring), 104.2 (1C, -<underline>C-</underline>CO-), 61.7(1C, -<underline>C</underline>-CH<sub>3</sub>), 45.1 (1C, -<underline>C</underline>-NH), 18.4 (1C, -CH<sub>3</sub>), 14.1 (1C, -CH<sub>3</sub>); elemental analysis: Calcd. for C<sub>14</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>: elemental analysis: C, 61.30; H, 6.61; N, 20.42%; found: C, 61.27; H, 6.62; N, 20.45%.</p></sec><sec id="sec2.4.2"><title>2.4.2. Ethyl 6-methyl-4-phenyl-2-(2-phenylhydrazono)-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1b)</title><p>The composition of 1b is as follows: grey solid; mw: 350.41; mp:184&#x000b0;C; IR (cm<sup>&#x02212;1</sup>): 3239.20 (NH), 3128.82 (Ph-CHstr), 2596.43 (C=N), 1715.02 (OCOEt); <sup>1</sup>H NMR (300&#x02009;MHz, DMSO- d<sub>6</sub>): <italic>&#x003b4;</italic> 11.12 (1H, s, NH), 9.34 (2H, s, NH), 7.35 (2H, dd, <italic>J</italic> = 7.33&#x02009;Hz, <italic>J</italic> = 7.37&#x02009;Hz Ph), 7.33 (2H, dd, <italic>J</italic> = 7.33&#x02009;Hz, <italic>J</italic> = 7.37&#x02009;Hz Ph), 7.29 (1H, d, <italic>J</italic> = 6.21&#x02009;Hz, Phenyl), 7.23 (2H, dd, <italic>J</italic> = 7.31&#x02009;Hz, <italic>J</italic> = 7.35&#x02009;Hz Ph), 7.20 (2H, dd, <italic>J</italic> = 7.31&#x02009;Hz, <italic>J</italic> = 7.35&#x02009;Hz Ph), 6.81 (1H, d, <italic>J</italic> = 6.21&#x02009;Hz, phenyl), 4.20 (2H, m, - CH<sub>2</sub>) 4.12 (1H, d, <italic>J</italic> = 6.21&#x02009;Hz, -CH), 2.26 (3H, s, -CH<sub>3</sub>), 1.29 (3H, s, -CH<sub>3</sub>); <sup>13</sup>C NMR (300&#x02009;MHz, DMSO-d<sub>6</sub>): 167.2 (1C, <underline>C</underline>=O), 160.3(1C, -<underline>C</underline>-CH<sub>3</sub>), 154.0 (1C, C=N), 143.3, 128.5, 126.9, 126.7(6C, Ar ring), 143.0, 113.9, 129.5, 122.4 (6C, Ar ring), 104.2 (1C, -<underline>C-</underline>CO-), 61.7 (1C, -<underline>C</underline>-CH<sub>3</sub>), 45.1(1C, -<underline>C</underline>-NH), 18.4 (1C, -CH<sub>3</sub>) 14.1 (1C, -CH<sub>3</sub>); elemental analysis: Calcd. for C<sub>20</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>: C, 68.55; H, 6.33; N, 15.99 %; found: C, 68.52; H, 6.37; N, 15.98%.</p></sec><sec id="sec2.4.3"><title>2.4.3. Ethyl 2-(carbamothioylimino)-6-methyl-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1c)</title><p>The composition of 1c is as follows: white solid; mw: 318.39; mp:236&#x000b0;C; IR (cm<sup>&#x02212;1</sup>): 3239.02 (NH), 3128.82 (Ph-CHstr), 2596.43 (C=N), 1715.02 (OCOEt), 1094.82 (C=S); <sup>1</sup>H NMR (300&#x02009;MHz, DMSO- d<sub>6</sub>): <italic>&#x003b4;</italic> 9.26 (2H, s, NH), 8.84 (2H, s, NH<sub>2</sub>), 7.33 (2H, dd, <italic>J</italic> = 7.33&#x02009;Hz, <italic>J</italic> = 7.37&#x02009;Hz Ph), 7.25 (1H, d, <italic>J</italic> = 6.21&#x02009;Hz, phenyl), 7.23 (2H, dd, <italic>J</italic> = 7.31&#x02009;Hz, <italic>J</italic> = 7.35&#x02009;Hz Ph), 4.20 (2H, m, - CH<sub>2</sub>), 4.10 (1H, d, <italic>J</italic> = 6.21&#x02009;Hz, -CH), 2.26 (3H, s, -CH<sub>3</sub>), 1.29 (3H, s, -CH<sub>3</sub>); <sup>13</sup>C NMR(300&#x02009;MHz, DMSO-d<sub>6</sub>): 190.0 (1C, C=S), 167.2 (1C, <underline>C</underline>=O), 160.3(1C, -<underline>C</underline>-CH<sub>3</sub>), 163.0 (1C, C=N), 143.3, 128.5, 126.9, 126.7 (6C, Ar ring), 104.2 (1C, -<underline>C-</underline>CO-), 61.7 (1C, -<underline>C</underline>-CH<sub>3</sub>), 45.1 (1C, -<underline>C</underline>-NH), 18.4 (1C, -CH<sub>3</sub>), 14.1 (1C, -CH<sub>3</sub>); elemental analysis: Calcd. for C<sub>15</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>S: C, 56.58; H, 5.70; N, 17.60%; found: C, 56.60; H, 5.71; N, 17.57%.</p></sec></sec><sec id="sec2.5"><title>2.5. Antioxidant&#x02013;(ABTS<sup>&#x000b7;+</sup>) Scavenging Activity</title><p>ABTS<sup>+</sup> (2,2&#x02032;-azino-bis(3-ethylbenzothiazoline-6-sulfonicacid)), the antioxidant radical scavenging activity, was checked with all compounds via spectrophotometric analysis according to the method descripted in Surendra Kumar et al. [<xref rid="B27" ref-type="bibr">27</xref>]. The ABTS<sup>&#x000b7;+</sup> radical scavenging is established and calculated the ability of antioxidants via characteristic absorption at 734&#x02009;nm for long-lived ABTS radical cation, which indicated that blue/green chromophore. The results are shown in <xref rid="tab1" ref-type="table">Table 1</xref>. The tested reaction mixture was prepared by 7&#x02009;mM aqueous ABTS with 2.45&#x02009;mM potassium per sulfate at 12&#x02009;h maintained in the dark room with formal temperature. Prior to the experiment, a range of absorbance 0.700 &#x000b1; 0.025 at 734&#x02009;nm was obtained by the ABTS<sup>&#x000b7;<bold>+</bold></sup> solution was diluted with phosphate buffer (0.1&#x02009;M, pH&#x02009;7.4) and added with 1&#x02009;mL of the diluted 1.5&#x02009;mL ethanolic solutions of 1a-c, Cu-Nps, and Cu-Nps-Pyr (1a-1c) with different concentrations (100&#x02009;<italic>&#x003bc;</italic>g/mL). After 30&#x02009;min, the percentage of inhibition was calculated at 734&#x02009;nm. Ethanol is used as a blank sample, following the formula used for analysis of the percentage of inhibition. 
<disp-formula id="eq1"><label>(1)</label><mml:math id="M1"><mml:mtable><mml:mtr><mml:mtd><mml:mtext>ABTS</mml:mtext><mml:mo>+</mml:mo><mml:mtext>scavenging</mml:mtext><mml:mtext/><mml:mtext>effect</mml:mtext><mml:mtext/><mml:mfenced open="(" close=")"><mml:mrow><mml:mi>%</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfenced open="[" close="]"><mml:mrow><mml:mfrac><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mtext>c</mml:mtext></mml:mrow></mml:msub><mml:mo>&#x02013;</mml:mo><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mtext>s</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mtext>c</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn><mml:mi>%</mml:mi><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula>where <italic>A</italic><sub>c</sub>&#x02009;=&#x02009;initial ABTS<sup>&#x000b7;<bold>+</bold></sup> absorbance and <italic>A</italic><sub>s</sub>&#x02009;=1a&#x02013;c, Cu-Nps, and Cu-Nps-Pyr (1a-1c) absorbance.</p></sec><sec id="sec2.6"><title>2.6. Inhibition of AAPH Assay Free Radical Analysis</title><p>This linoleic acid peroxidation assay was achieved and followed the methods of Surendra Kumar et al. [<xref rid="B27" ref-type="bibr">27</xref>]. All values were carried out in triplicate, with the consistent data, provided in <xref rid="tab1" ref-type="table">Table 1</xref>. The oxidation of linoleic acid production was analyzed by conjugated diene hydroperoxide in an aqueous distribution was observed at 234&#x02009;nm, [<xref rid="B28" ref-type="bibr">28</xref>] with AAPH (2,2&#x02032;-azobis(2-amidinopropane) dihydrochloride) used as a free radical initiator. For UV cuvette solution preparation, 1&#x02009;mL aliquot of a 16&#x02009;mM linoleic acid was added to 1&#x02009;mL of 0.05&#x02009;M phosphate buffer(pH&#x02009;7.4), thermostatic at 37&#x000b0;C and addition of 1&#x02009;mL of the 40&#x02009;mM AAPH solution. Oxidation reaction was monitored in occurrence of 1&#x02009;mL of the tested compounds 1a-c, Cu-Nps, and Cu-Nps-Pyr (1a-1c). In the absence of antioxidants, the lipid oxidation was monitored in DMSO mixed compounds. The rate of oxidation was monitored at 37&#x000b0;C and absorption recorded at 234&#x02009;nm due to the formation of a conjugated diene hydroperoxide.</p><p>The percentage of linoleic acid oxidation inhibition was calculated as follows:
<disp-formula id="eq2"><label>(2)</label><mml:math id="M2"><mml:mtable><mml:mtr><mml:mtd><mml:mi>%</mml:mi><mml:mtext>Inhibition</mml:mtext><mml:mo>=</mml:mo><mml:mfenced open="[" close="]"><mml:mrow><mml:mfrac><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02013;</mml:mo><mml:mtext>rate</mml:mtext><mml:mtext/><mml:mtext>of</mml:mtext><mml:mtext/><mml:mtext>absorbance</mml:mtext><mml:mtext/><mml:mtext>with</mml:mtext><mml:mtext/><mml:mtext>test</mml:mtext><mml:mtext/><mml:mtext>compound</mml:mtext></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mtext>rate</mml:mtext><mml:mtext/><mml:mtext>of</mml:mtext><mml:mtext/><mml:mtext>absorbance</mml:mtext><mml:mtext/><mml:mtext>with</mml:mtext><mml:mtext/><mml:mtext>solvent</mml:mtext><mml:mtext/><mml:mtext>control</mml:mtext></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn><mml:mi>%</mml:mi><mml:mo>.</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p></sec><sec id="sec2.7"><title>2.7. Cytotoxic Activity</title><p>The synthesized compounds 1a-c, Cu-Nps, and Cu-Nps -Pyr (1a-1c) were screened for cytotoxic activity, and we followed the methods of Surendra Kumar et al. [<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B29" ref-type="bibr">29</xref>]. The 100&#x02009;<italic>&#x003bc;</italic>M (MTT anticancer assay) concentration treated with test compounds for 48&#x02009;h was used by three cell lines (HepG2, HeLa, and MCF-7), and standard of doxorubicin was selected in this screening.</p><p>The results were analyzed between the growth percentage of treated cells and untreated control cells. Sample preparation, 0.1&#x02009;mL of the test solution (6.25&#x02013;100&#x02009;<italic>&#x003bc;</italic>g in 1% DMSO), and 0.1&#x02009;mL aliquot of the cell suspension (5 &#x000d7; 10<sup>6</sup> cells/100&#x02009;<italic>&#x003bc;</italic>L) were added and kept in an incubator (5% CO<sub>2</sub>) at 37&#x000b0;C for 72&#x02009;h. The blank sample checked only the cell suspension, and the control wells contained 1% DMSO and the cell suspension. After 72&#x02009;h, 20&#x02009;<italic>&#x003bc;</italic>L of MTT was added, and the plates were kept in the CO<sub>2</sub> incubator for 2&#x02009;h, followed by the addition of propanol (100&#x02009;<italic>&#x003bc;</italic>L). The absorption data (562&#x02009;nm) were obtained by 27-well plates on an ELISA reader; the test sample was prepared by aluminum foil covered with subsequently agitated in a rotary shaker for 10&#x02013;20&#x02009;min.</p></sec><sec id="sec2.8"><title>2.8. Statistical Analysis</title><p>Antioxidant activities results were calculated through 3 independent evaluations, and Microsoft Excel was used to analysis the standard deviations (SD) of each compound.</p></sec></sec><sec id="sec3"><title>3. Result and Discussion</title><p>The one-pot multicomponent 2-pyrimidinamine was synthesized with in high yields. The most important factor was only excellent yield, which was a performance of suitable catalysis with aromatic aldehyde performance including hydroxyl groups reacted efficiently.</p><p>A series of compounds were prepared via optimizing the reaction conditions, for instance of reaction involved among benzaldehyde, ethyl acetoacetate, substituted amine, and urea using Cu-Nps as a catalyst in a suitable solvent (<xref ref-type="fig" rid="sch1">Scheme 1</xref>). The amount of Cu-Nps was changed subsequently from 0&#x02009;mol% to 5&#x02009;mol% under solvent-free conditions, as a result of the optimized mole percentage and the 88% yield performance obtained at 1&#x02009;mol% concentration. Therefore, the results directed that 1&#x02009;mol% of Cu-Nps is enough for the synthesis of the 2-pyrimidinamine compound. The synthesized Cu-Nps were characterized by UV, FT-IR spectroscopy, SEM, XRD, EDX, AFM (atomic force microscopy), profile, waviness, and roughness analyses.</p><sec id="sec3.1"><title>3.1. FT-IR Studies</title><p>The main characteristic experimental vibrations of Cu-Nps are obtained from FT-IR shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>. The literature data of IR values were referred to the analysis of the vibrational frequency presence in the compounds. For spectral values of O&#x02212;H and C&#x02212;H stretching, the vibration frequency range was obtained at 4000&#x02212;2000&#x02009;cm<sup>&#x02212;1</sup>. The O&#x02212;H stretching in water molecules was assigned at 3432&#x02009;cm<sup>&#x02212;1</sup> for Cu-Nps. The mode of the antisymmetric and the symmetric carboxylate groups was observed at 1593&#x02009;cm<sup>&#x02212;1</sup> (s, FT-IR) and 1391&#x02009;cm<sup>&#x02212;1</sup>(vs. FT-IR), respectively. Biphenyl group was found in the IR range between 1600 and 1400&#x02009;cm<sup>&#x02212;1</sup>, respectively. The COOH bends and C-N (Bz) stretching modes was observed at 1235&#x02009;cm<sup>&#x02212;1,</sup> respectively.</p></sec><sec id="sec3.2"><title>3.2. UV-Visible Studies</title><p>Spectrophotometric analysis was carried out for the Cu-Np catalyst. 6.25&#x02009;mM of telmisartan was added with different copper concentrations with the addition of 1&#x02009;M NaOH (pH&#x02009;7) for every tested compound. The UV-visible spectra are shown in <xref ref-type="fig" rid="fig4">Figure 4</xref>. The Cu-Nps showed absorption bands located at 530&#x02009;nm (sh).</p></sec><sec id="sec3.3"><title>3.3. SEM and EDX Analyses</title><p>
<xref ref-type="fig" rid="fig5">Figure 5</xref> illustrates SEM images of Cu-Nps obtained in water (a) and in formamide mixture (b). The telmisartan-mediated Cu-Nps in the formamide mixture shows cubic in nature with size in the range of 1&#x02009;<italic>&#x003bc;</italic>m (c). <xref ref-type="fig" rid="fig6"> Figure 6</xref> illustrates the EDX of Cu-Nps that exhibited the elements (Cu, C, and O) in the nanoparticle, thereby confirming the formation of the nanoparticle. <xref rid="tab2" ref-type="table"> Table 2</xref> shows the EDX analysis of percentage of elements present in the Cu-Np catalyst.</p></sec><sec id="sec3.4"><title>3.4. Powder X-Ray Diffraction Studies</title><p>The structural analysis and phase crystallinity of the synthesized Cu-Nps were examined via the powder X-ray diffraction method. <xref ref-type="fig" rid="fig7"> Figure 7</xref> signifies a Cu nanoparticle diffraction pattern at a 2<italic>&#x003b8;</italic> value of 43.20&#x000b0;, 50.42&#x000b0;, and 74.15&#x000b0; respect to (111), (200), and (220) planes individually; it conformed the formation of copper cubic lattice. JCPDS No. 040836 indicates the good agreement and comparison with the standard pattern for pure face centered cubic phase of copper nanoparticles. There are no impurity peaks observed. The strong peaks indicate the highly crystalline nature of the formed nanoparticles. From the observed main diffracted peak, the average crystalline size can be calculated using the Scherer equation. 
<disp-formula id="eq3"><label>(3)</label><mml:math id="M3"><mml:mtable><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mtext>hkl</mml:mtext></mml:mrow></mml:mfenced></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>k</mml:mi><mml:mi>&#x003bb;</mml:mi></mml:mrow><mml:mrow><mml:mi>&#x003b2;</mml:mi><mml:mi mathvariant="normal">cos</mml:mi><mml:mi>&#x003b8;</mml:mi></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula>where <italic>D</italic><sub>(hkl)</sub> is the average crystalline size, <italic>k</italic> is shape constant (0.89), <italic>&#x003bb;</italic> is the incident X-ray (CuK<italic>&#x003b1;</italic> source, <italic>&#x003bb;</italic> = 0.15405&#x02009;nm), <italic>&#x003b2;</italic> is the full-width half-maximum, and <italic>&#x003b8;</italic> is the incident angle of X-ray. The average crystallite size of the synthesized copper nanoparticles was 25.41&#x02009;nm.</p></sec><sec id="sec3.5"><title>3.5. Atomic Force Microscope Studies</title><p>
<xref ref-type="fig" rid="fig8">Figure 8</xref> shows AFM images of Cu-Nsp. AFM image indicates the filtering procedure at cut-off frequency values at 4&#x02009;<italic>&#x003bc;</italic>m and Cu-Nsp profile particle size; performance is presented in <xref ref-type="fig" rid="fig8">Figure 8(b)</xref>, which obtained a value of 253&#x02009;nm for the unfiltered profile. Figures <xref ref-type="fig" rid="fig8">8(c)</xref> and <xref ref-type="fig" rid="fig8">8(d)</xref> indicated the Cu-Np waviness and roughness, which were 234&#x02009;nm for waviness and 14&#x02009;nm for the roughness profile. Therefore, such values indicate that the unfiltered roughness parameter of shape and binding dominate Cu nanoparticles.</p></sec><sec id="sec3.6"><title>3.6. TGA/DTA Studies</title><p>The compound was displayed by total weight loss in three stages. In the first stage, the weight loss occurred in the temperature range about 40-220&#x000b0;C representing the vapor liberation in the sample. The weight loss befell in the second stage at the temperature range between 220 and 450&#x000b0;C consistent to the liberation of vapor from the inner apertures of Cu. The weight loss in the third stage happens between the temperature ranges of 450-800&#x000b0;C display indulgences of carbonaceous material of the sample. Organic material presence in the sample, was observed at exothermic peak of 290&#x000b0;C. The TGA/DTA profile for the Cu-Np precursor was shown in <xref ref-type="fig" rid="fig9">Figure 9</xref>.</p></sec><sec id="sec3.7"><title>3.7. Particle Size Analyzer Studies</title><p>For a particle size analyzer, the first peak indicates 206.4&#x02009;nm diameter and standard deviation 38.4&#x02009;nm, which indicates 206.4&#x02009;nm average nanoparticle presence in the target nanocatalysis. <xref ref-type="fig" rid="fig10"> Figure 10</xref> shows different intensity vs. diameter of the first peak of Cu-Nps.</p></sec><sec id="sec3.8"><title>3.8. Catalyst Recovery Studies</title><p>
<xref ref-type="fig" rid="fig11">Figure 11</xref> indicated the recovery of the catalyst with salvaged for at least 10 run times and slight loss in catalytic activity. The lessening of activity could be detected with the regenerated catalyst on salvaging due to surface area of the catalyst during the reaction or partial loss of basic sites/regeneration. The values are shown in <xref rid="tab3" ref-type="table">Table 3</xref>.</p><p>The application of the catalyst was inspected via optimizing the reaction conditions. A number of aromatic aldehydes were selected to go through the condensation reaction with Cu-Nps (1&#x02009;mol %) catalytic at room temperature in solvent-free settings, the yield reported in <xref rid="tab3" ref-type="table">Table 3</xref>. The Cu-catalyzed performance and reaction mechanism are shown in <xref ref-type="fig" rid="sch2">Scheme 2</xref>.</p><p>The intermediate of acyl imine formed between urea reacts with primary amine; for the next step, acyl imine reacted with aldehyde to give the guanidine core, which is actuated by copper catalysis. Step 3 was addition reaction between <italic>&#x003b2;</italic>-dicarbonyl with 1-benzylidene-2-R-guanidine, then cyclized to afford the 2-aminopyrimidine derivatives. In conclusion, the simple and efficient synthesis of 2-aminopyrimidine uses Cu-Nps under solvent-free conditions. We developed the methodology and environmentally safe synthesis of the 2-aminopyrimidine derivative with good yields.</p><p>Compounds 1a-1c were synthesized by condensation method. The compounds 1a-1c physicochemical data are represented in <xref rid="tab4" ref-type="table">Table 4</xref> and its catalyst performance is shown in <xref rid="tab5" ref-type="table">Table 5</xref>. The compounds were confirmed via FT-IR, <sup>1</sup>H and <sup>3</sup>C NMR spectra, and elemental analyses. The IR absorption bands of compound 1a show the frequency range between 2584 and 2596 and 3239 and 3246&#x02009;cm<sup>&#x02212;1</sup> corresponding to the C=N and NH groups, respectively.</p><p>For compound 1a, the <sup>1</sup>H NMR spectral value obtained a sharp singlet at <italic>&#x003b4;</italic> 9.20 for NH proton and a singlet at <italic>&#x003b4;</italic> 4.16 for -CH- proton, <sup>13</sup>C NMR spectral values at <italic>&#x003b4;</italic> 167.2 and <italic>&#x003b4;</italic> 154.0&#x02009;ppm corresponding to C=O and C=N carbons, respectively. The IR absorption bands show that compound 1b frequency ranges between 3239 and 3246 and 2584 and 2596&#x02009;cm<sup>&#x02212;1</sup> corresponding to the NH and C=N groups, respectively. For compound 1b, <sup>1</sup>H NMR spectral value obtained a sharp singlet at <italic>&#x003b4;</italic> 9.34 for NH proton and a singlet at <italic>&#x003b4;</italic> 4.12 for -CH- proton, <sup>13</sup>C NMR spectra of compound peaks at <italic>&#x003b4;</italic> 167.0 and <italic>&#x003b4;</italic>154.8&#x02009;ppm corresponding to C=O and C=N carbons, respectively.</p><p>For compound 1c, IR spectra show absorption bands in 2584&#x02013;2596 and 3239-3246&#x02009;cm<sup>&#x02212;1</sup> corresponding to the C=N and NH groups, respectively. For compound 1c, <sup>1</sup>H NMR spectral value obtained a sharp singlet at <italic>&#x003b4;</italic> 9.26 for NH proton and a singlet at <italic>&#x003b4;</italic> 4.10 for -CH- proton; <sup>13</sup>C NMR spectral value obtained the peaks at <italic>&#x003b4;</italic> 163.0, 167.2, and 190.0&#x02009;ppm corresponding to C=N, C=O, and C=S carbons, respectively.</p><p>
<xref ref-type="fig" rid="sch3">Scheme 3</xref> indicates that the mechanism of expected product and unexpected copper nanoparticles connected 2-pyrimidine compounds; this mechanism clearly indicated the necessity for evaluation of the biological activity in 1a&#x02013;c, Cu-Nps, and unexpected copper nanoparticles connected 2-pyrimidine Cu-Nps-Pyr (1a-1c) compounds.</p></sec><sec id="sec3.9"><title>3.9. ABTS<sup>&#x000b7;+</sup> Radical Scavenging Activity</title><p>The antioxidant activity was carried out based on a decolorization technique using the ABTS radical assay, with the generation of the stable blue/green ABTS<sup>&#x000b7;+</sup> radical formation. Among the synthesized compounds, Cu-Nps-Pyr-1b showed capable ABTS<sup>&#x000b7;+</sup> scavenging activities of 97.2%, compared with Trolox standard (<xref rid="tab1" ref-type="table">Table 1</xref>).</p><p>This study, containing both 2-pyrimidinamine and Cu-Nps, shows the capability to scavenge ABTS<sup>&#x000b7;+</sup> assays compared with standard; the mechanism is represented in <xref ref-type="fig" rid="sch4">Scheme 4</xref>.</p></sec><sec id="sec3.10"><title>3.10. Cu-Nps&#x02013;Pyr-1c-Linoleic Acid Peroxidation-Inhibition</title><p>The Cu-Nsp with 2-pyrimidinamine combination was highly responsive to oxidative changes and inhibition in linoleic acid peroxidation screening. The hydrophilic AAPH initiator was used to measure the conjugated diene hydroperoxide formation at 234&#x02009;nm by spectrophotometric analysis. Indeed, AAPH produced the free radicals at 37&#x000b0;C, which was an act of spontaneous decomposition. Here, R&#x02013;N=N&#x02013;R indicates the radical initiator, and LOO<sup>&#x000b7;</sup> denotes a linoleic peroxy radical, and LH stands for linoleic acid. The radicals R<sup>&#x000b7;</sup> was produced via immediately reacting with oxygen and causing the oxidation of lipids. The mechanism of reaction is represented in <xref ref-type="fig" rid="sch5">Scheme 5</xref>.</p><p>The Cu-Nsp with 2-pyrimidinamine derivatives was performed by hydrogen donor antioxidants (AOH), steadying and postponing the free radicals of oxidation lipids. In <italic>in vitro</italic> studies of free radical fabrication, an azo compound was causing free radicals by impulsive thermal decomposition. Alkylperoxy free radicals were produced via the water-soluble AAPH used as a hygienic and governable source thermally. AAPH assay was achieved to enhance the antioxidant activity of Cu-Nsp with 2-pyrimidinamine; the compound 1c and Cu-Nps-Pyr-1c are awarding activities of 75.6 and 91.2%, respectively, at a concentration of 100&#x02009;<italic>&#x003bc;</italic>g/mL.</p></sec><sec id="sec3.11"><title>3.11. Cytotoxic Activity</title><p>The results of each compound were reported in <xref rid="tab6" ref-type="table">Table 6</xref>. The results show the contacts of LC<sub>50</sub>, TGI, and GI<sub>50</sub> values. The compound 1a (GI<sub>50</sub> = 0.69<italic>&#x003bc;</italic>M) was high, while Cu-Nps-Pyr-1a (GI<sub>50</sub> = 0.01&#x02009;<italic>&#x003bc;</italic>m) showed a significant activity against the HeLa cancer cell line. The compound 1b (GI<sub>50</sub> = 02.1&#x02009;<italic>&#x003bc;</italic>M) and Cu-Nps-Pyr-1b (GI<sub>50</sub> = 0.01&#x02009;<italic>&#x003bc;</italic>M) showed rightful activity against the HepG2 cell line compared with standard doxorubicin. All compounds displayed a moderate activity against all the cell line, whereas when compound with Cu nanoparticles, it is becoming highly responsive in cytotoxic scanning.</p></sec></sec><sec id="sec4"><title>4. Conclusion</title><p>In conclusion, for copper nanoparticles mediated by the telmisartan drug, the Cu-Nsp was characterized by UV and FT-IR spectroscopy, scanning electron microscopy, X-Ray, EDX, AFM (atomic force microscopy), profile, waviness, roughness analysis, TGA studies and particle size analyzer. Synthesized Cu-Nps were used as catalysis for preparation of pyrimidinamine via the Biginelli multicomponent cyclocondensation reaction. The Cu-Nsp was a significantly active catalyst and gave excellent yields, and also recycling of the catalyst is very easy in this process. Bioactivity of 2-pyrimidinamine was a significant activity against performance of ABTS<sup>&#x000b7;+</sup> and linoleic acid peroxidation, while Cu-Nsp was moderately active in antioxidant screening; therefore, designed 2-pyrimidinamine with Cu-Nsp gave a noble result when compared with commercial drugs. Particularly, Cu-Nps-Pyr-1b was a potential activity (&#x0003e;90%) against ABTS<sup>&#x000b7;+</sup> and AAPH assays, as compared with the Trolox standard. In cytotoxicity activity, the compound Cu-Nps-Pyr-1a was perceived for (GI<sub>50</sub> = 0.01&#x02009;<italic>&#x003bc;</italic>m) against the HeLa cell line compared with doxorubicin. It is noteworthy that Cu-Nps with 2-pyrimidinamine and their derivatives are medicinally important as anticancer treatment, and future investigation of <italic>in vivo</italic> screening and the mechanism of action is currently undergoing study.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was funded by Researchers Supporting Project number (RSP-2020/27), King Saud University, Riyadh, Saudi Arabia.</p></ack><sec sec-type="data-availability"><title>Data Availability</title><p>The data used to support the findings of this study are available from the corresponding author upon request.</p></sec><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that they have no conflict of interest.</p></sec><sec><title>Authors' Contributions</title><p>A.I conceived, designed, and coordinated the study. R.S, S.A, and C.S collected the data. N.A.A. was responsible for the statistical analysis. All authors contributed to data analysis and interpretation. All authors read, reviewed, and approved this current version for publication.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>B.</given-names></name><name><surname>Hong</surname><given-names>F.</given-names></name><name><surname>Kohm</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Synthesis, SAR, and antitumor properties of diamino- C , N -diarylpyrimidine positional isomers: inhibitors of lysophosphatidic acid acyltransferase-<italic>&#x003b2;</italic></article-title><source><italic toggle="yes">Bioorganic &#x00026; Medicinal Chemistry Letters</italic></source><year>2004</year><volume>14</volume><issue>9</issue><fpage>2303</fpage><lpage>2308</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2004.01.104</pub-id><pub-id pub-id-type="other">2-s2.0-1842690073</pub-id><?supplied-pmid 15081029?><pub-id pub-id-type="pmid">15081029</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>L. S.</given-names></name><name><surname>Zhao</surname><given-names>L. X.</given-names></name><name><surname>Choi</surname><given-names>W. J.</given-names></name><etal/></person-group><article-title>Synthesis and antitumor activity of fluorocyclopentenyl- pyrimidines</article-title><source><italic toggle="yes">Nucleosides Nucleotides Nucleic Acids</italic></source><year>2007</year><volume>26</volume><issue>6-7</issue><fpage>713</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1080/15257770701490852</pub-id><pub-id pub-id-type="other">2-s2.0-36949012733</pub-id><pub-id pub-id-type="pmid">18066886</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>Y. W.</given-names></name><name><surname>Li</surname><given-names>Y. H.</given-names></name><name><surname>Li</surname><given-names>Z. M.</given-names></name></person-group><article-title>Design, synthesis and herbicidal activity of novel sulfonylureas containing monosubstituted pyrimidine moiety</article-title><source><italic toggle="yes">Chemical Journal of Chinese Universities</italic></source><year>2013</year><volume>34</volume><fpage>1416</fpage><lpage>1422</lpage><pub-id pub-id-type="doi">10.7503/cjcu20120972</pub-id><pub-id pub-id-type="other">2-s2.0-84879522834</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milling</surname><given-names>R. J.</given-names></name><name><surname>Richardson</surname><given-names>C. J.</given-names></name></person-group><article-title>Mode of action of the anilino-pyrimidine fungicide pyrimethanil. 2. Effects on enzyme secretion <italic>in Botrytis cinerea</italic></article-title><source><italic toggle="yes">Pesticide Science</italic></source><year>1995</year><volume>45</volume><issue>1</issue><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1002/ps.2780450107</pub-id><pub-id pub-id-type="other">2-s2.0-84995002698</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernier</surname><given-names>J. L.</given-names></name><name><surname>Henichart</surname><given-names>J. P.</given-names></name><name><surname>Warin</surname><given-names>V.</given-names></name><name><surname>Baert</surname><given-names>F.</given-names></name></person-group><article-title>Synthesis and structure-activity relationship of a pyrimido[4,5-d]pyrimidine derivative with antidepressant activity</article-title><source><italic toggle="yes">Journal of Pharmaceutical Sciences</italic></source><year>1980</year><volume>69</volume><issue>11</issue><fpage>1343</fpage><lpage>1345</lpage><pub-id pub-id-type="doi">10.1002/jps.2600691128</pub-id><pub-id pub-id-type="other">2-s2.0-0019302193</pub-id><?supplied-pmid 6256515?><pub-id pub-id-type="pmid">6256515</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>K. H.</given-names></name><name><surname>Jeong</surname><given-names>S.</given-names></name></person-group><article-title>Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors</article-title><source><italic toggle="yes">Bioorganic and Medicinal Chemistry Letters</italic></source><year>2011</year><volume>21</volume><issue>14</issue><fpage>4203</fpage><lpage>4205</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2011.05.081</pub-id><pub-id pub-id-type="other">2-s2.0-79959893500</pub-id><?supplied-pmid 21684737?><pub-id pub-id-type="pmid">21684737</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawser</surname><given-names>S.</given-names></name><name><surname>Lociuro</surname><given-names>S.</given-names></name><name><surname>Islam</surname><given-names>K.</given-names></name></person-group><article-title>Dihydrofolate reductase inhibitors as antibacterial agents</article-title><source><italic toggle="yes">Biochemical Pharmacology</italic></source><year>2006</year><volume>71</volume><issue>7</issue><fpage>941</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2005.10.052</pub-id><pub-id pub-id-type="other">2-s2.0-33644508373</pub-id><?supplied-pmid 16359642?><pub-id pub-id-type="pmid">16359642</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hockov&#x000e1;</surname><given-names>D.</given-names></name><name><surname>Hol&#x000fd;</surname><given-names>A.</given-names></name><name><surname>Masoj&#x000ed;dkov&#x000e1;</surname><given-names>M.</given-names></name><etal/></person-group><article-title>5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidinesAcyclic nucleoside phosphonate analogues with antiviral activity</article-title><source><italic toggle="yes">Journal of Medicinal Chemistry</italic></source><year>2003</year><volume>46</volume><issue>23</issue><fpage>5064</fpage><lpage>5073</lpage><pub-id pub-id-type="doi">10.1021/jm030932o</pub-id><pub-id pub-id-type="other">2-s2.0-0242299576</pub-id><?supplied-pmid 14584956?><pub-id pub-id-type="pmid">14584956</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bendich</surname><given-names>A.</given-names></name><name><surname>Clements</surname><given-names>G. C.</given-names></name></person-group><article-title>A revision of the structural formulation of vicine and its pyrimidine aglucone, divicine</article-title><source><italic toggle="yes">Biochimica et Biophysica Acta</italic></source><year>1953</year><volume>12</volume><issue>1-2</issue><fpage>462</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1016/0006-3002(53)90166-8</pub-id><pub-id pub-id-type="other">2-s2.0-0042451128</pub-id><pub-id pub-id-type="pmid">13115456</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamed</surname><given-names>A. N. E.</given-names></name><name><surname>Schmitz</surname><given-names>R.</given-names></name><name><surname>Bergermann</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Bioactive pyrrole alkaloids isolated from the Red Sea: marine sponge Stylissa carteri</article-title><source><italic toggle="yes">Zeitschrift f&#x000fc;r Naturforschung</italic></source><year>2018</year><volume>73</volume><issue>5-6</issue><fpage>199</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1515/znc-2017-0161</pub-id><pub-id pub-id-type="other">2-s2.0-85041612601</pub-id><pub-id pub-id-type="pmid">29353267</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Assmann</surname><given-names>M.</given-names></name><name><surname>Van Soest</surname><given-names>R. W. M.</given-names></name><name><surname>Kock</surname><given-names>M.</given-names></name></person-group><article-title>New antifeedant bromopyrrole alkaloid from the Caribbean sponge <italic>Stylissa caribica</italic></article-title><source><italic toggle="yes">Journal of Natural Products</italic></source><year>2001</year><volume>64</volume><issue>10</issue><fpage>1345</fpage><lpage>1347</lpage><pub-id pub-id-type="doi">10.1021/np000482s</pub-id><pub-id pub-id-type="other">2-s2.0-0034763640</pub-id><?supplied-pmid 11678664?><pub-id pub-id-type="pmid">11678664</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlberg</surname><given-names>B. E.</given-names></name><name><surname>Lins</surname><given-names>L. E.</given-names></name><name><surname>Hermansson</surname><given-names>K.</given-names></name></person-group><article-title>Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension</article-title><source><italic toggle="yes">Journal of Hypertension</italic></source><year>1999</year><volume>17</volume><issue>2</issue><fpage>293</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1097/00004872-199917020-00015</pub-id><pub-id pub-id-type="other">2-s2.0-0032970904</pub-id><?supplied-pmid 10067800?><pub-id pub-id-type="pmid">10067800</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rushworth</surname><given-names>G. F.</given-names></name><name><surname>Megson</surname><given-names>I. L.</given-names></name></person-group><article-title>Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits</article-title><source><italic toggle="yes">Pharmacology &#x00026; Therapeutics</italic></source><year>2014</year><volume>141</volume><issue>2</issue><fpage>150</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2013.09.006</pub-id><pub-id pub-id-type="other">2-s2.0-84891883913</pub-id><?supplied-pmid 24080471?><pub-id pub-id-type="pmid">24080471</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>D.</given-names></name><name><surname>Jiang</surname><given-names>D.</given-names></name><name><surname>Kutyreff</surname><given-names>C. J.</given-names></name><etal/></person-group><article-title>Molybdenum-based nanoclusters act as antioxidants and ameliorate acute kidney injury in mice</article-title><source><italic toggle="yes">Nature Communications</italic></source><year>2018</year><volume>9</volume><issue>1</issue><fpage>5421</fpage><lpage>5432</lpage><pub-id pub-id-type="doi">10.1038/s41467-018-07890-8</pub-id><pub-id pub-id-type="other">2-s2.0-85058906992</pub-id><?supplied-pmid 30575745?><pub-id pub-id-type="pmid">30575745</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okusa</surname><given-names>M. D.</given-names></name><name><surname>Rosner</surname><given-names>M. H.</given-names></name><name><surname>Kellum</surname><given-names>J. A.</given-names></name><name><surname>Ronco</surname><given-names>C.</given-names></name><name><surname>Acute Dialysis Quality Initiative XIII Workgroup</surname></name></person-group><article-title>Therapeutic targets of human AKI: harmonizing human and animal AKI</article-title><source><italic toggle="yes">Journals of the American Society of Nephrology</italic></source><year>2016</year><volume>27</volume><issue>1</issue><fpage>44</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1681/asn.2015030233</pub-id><pub-id pub-id-type="other">2-s2.0-84954456087</pub-id><?supplied-pmid 26519086?><pub-id pub-id-type="pmid">26519086</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pannu</surname><given-names>N.</given-names></name><name><surname>Manns</surname><given-names>B.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Tonelli</surname><given-names>M.</given-names></name></person-group><article-title>Systematic review of the impact of N-acetylcysteine on contrast nephropathy</article-title><source><italic toggle="yes">Kidney International</italic></source><year>2004</year><volume>65</volume><issue>4</issue><fpage>1366</fpage><lpage>1374</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00516.x</pub-id><pub-id pub-id-type="other">2-s2.0-1642545171</pub-id><?supplied-pmid 15086476?><pub-id pub-id-type="pmid">15086476</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Xiao</surname><given-names>B.</given-names></name><name><surname>Xiang</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Ultrasmall copper-based nanoparticles for reactive oxygen species scavenging and alleviation of inflammation related diseases</article-title><source><italic toggle="yes">Nature Communications</italic></source><year>2020</year><volume>11</volume><issue>1</issue><fpage>2788</fpage><lpage>2804</lpage><pub-id pub-id-type="doi">10.1038/s41467-020-16544-7</pub-id><?supplied-pmid 32493916?><pub-id pub-id-type="pmid">32493916</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>N.</given-names></name><name><surname>Ramamoorthy</surname><given-names>M.</given-names></name><name><surname>Lyon</surname><given-names>D.</given-names></name><name><surname>Jones</surname><given-names>K.</given-names></name><name><surname>Duttaroy</surname><given-names>A.</given-names></name></person-group><article-title>Mechanism of silver nanoparticles action on insect pigmentation reveals intervention of copper homeostasis</article-title><source><italic toggle="yes">PLoS ONE</italic></source><year>2013</year><volume>8</volume><issue>1</issue><fpage>p. e53186</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0053186</pub-id><pub-id pub-id-type="other">2-s2.0-84872044472</pub-id><pub-id pub-id-type="pmid">23308159</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotynia</surname><given-names>A.</given-names></name><name><surname>Janek</surname><given-names>T.</given-names></name><name><surname>Czy&#x0017c;nikowska</surname><given-names>&#x0017b;.</given-names></name><name><surname>Bieli&#x00144;ska</surname><given-names>S.</given-names></name><name><surname>Kamysz</surname><given-names>W.</given-names></name><name><surname>Brasu&#x00144;</surname><given-names>J.</given-names></name></person-group><article-title>The analysis of Cu(II)/Zn(II) cyclopeptide system as potential Cu,ZnSOD mimic center</article-title><source><italic toggle="yes">International Journal of Peptide Research and Therapeutics</italic></source><year>2017</year><volume>23</volume><issue>4</issue><fpage>431</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1007/s10989-017-9574-8</pub-id><pub-id pub-id-type="other">2-s2.0-85012937680</pub-id><pub-id pub-id-type="pmid">29170621</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>E. I.</given-names></name><name><surname>Lowery</surname><given-names>M. D.</given-names></name></person-group><article-title>Electronic structure contributions to function in bioinorganic chemistry</article-title><source><italic toggle="yes">Science</italic></source><year>1993</year><volume>259</volume><issue>5101</issue><fpage>1575</fpage><lpage>1581</lpage><pub-id pub-id-type="doi">10.1126/science.8384374</pub-id><pub-id pub-id-type="other">2-s2.0-0027914978</pub-id><?supplied-pmid 8384374?><pub-id pub-id-type="pmid">8384374</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cass</surname><given-names>A. E.</given-names></name><name><surname>Hill</surname><given-names>H. A.</given-names></name></person-group><article-title>Copper proteins and copper enzymes</article-title><source><italic toggle="yes">Ciba Foundation Symposium</italic></source><year>2008</year><volume>79</volume><fpage>71</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1002/9780470720622.ch5</pub-id><?supplied-pmid 6907091?><pub-id pub-id-type="pmid">6907091</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>L.</given-names></name><name><surname>Yuan</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Majeed</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>G.</given-names></name></person-group><article-title>Copper nanoclusters as peroxidase mimetics and their applications to H<sub>2</sub>O<sub>2</sub> and glucose detection</article-title><source><italic toggle="yes">Analytica Chimica Acta</italic></source><year>2013</year><volume>762</volume><fpage>83</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.aca.2012.11.056</pub-id><pub-id pub-id-type="other">2-s2.0-84872414316</pub-id><?supplied-pmid 23327949?><pub-id pub-id-type="pmid">23327949</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>W. C.</given-names></name><name><surname>Lyu</surname><given-names>L. M.</given-names></name><name><surname>Yang</surname><given-names>Y. C.</given-names></name><name><surname>Huang</surname><given-names>M. H.</given-names></name></person-group><article-title>Synthesis of Cu<sub>2</sub>O nanocrystals from cubic to rhombic dodecahedral structures and their comparative photocatalytic activity</article-title><source><italic toggle="yes">Journal of the American Chemical Society</italic></source><year>2011</year><volume>134</volume><issue>2</issue><fpage>1261</fpage><lpage>1267</lpage><pub-id pub-id-type="doi">10.1021/ja209662v</pub-id><pub-id pub-id-type="other">2-s2.0-84862908664</pub-id><?supplied-pmid 22257266?><pub-id pub-id-type="pmid">22257266</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Kang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Octahedral Cu<sub>2</sub>O@Co(OH)<sub>2</sub> nanocages with hierarchical Flake&#x02010;Like walls and yolk-shell structures for enhanced electrocatalytic activity</article-title><source><italic toggle="yes">ChemCatChem</italic></source><year>2019</year><volume>11</volume><issue>10</issue><fpage>2520</fpage><lpage>2525</lpage><pub-id pub-id-type="doi">10.1002/cctc.201900036</pub-id><pub-id pub-id-type="other">2-s2.0-85064746033</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C. L.</given-names></name><name><surname>Weng</surname><given-names>W. L.</given-names></name><name><surname>Huang</surname><given-names>Y. S.</given-names></name><name><surname>Liao</surname><given-names>C. N.</given-names></name></person-group><article-title>Enhanced photolysis stability of Cu<sub>2</sub>O grown on cu nanowires with nanoscale twin boundaries</article-title><source><italic toggle="yes">Nanoscale</italic></source><year>2019</year><volume>11</volume><issue>29</issue><fpage>13709</fpage><lpage>13713</lpage><pub-id pub-id-type="doi">10.1039/C9NR01406C</pub-id><pub-id pub-id-type="other">2-s2.0-85069669566</pub-id><?supplied-pmid 31194206?><pub-id pub-id-type="pmid">31194206</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gawande</surname><given-names>M. B.</given-names></name><name><surname>Goswami</surname><given-names>A.</given-names></name><name><surname>Felpin</surname><given-names>F. X.</given-names></name><etal/></person-group><article-title>Cu and cu-based nanoparticles: synthesis and applications in catalysis</article-title><source><italic toggle="yes">Chemical Reviews</italic></source><year>2016</year><volume>116</volume><issue>6</issue><fpage>3722</fpage><lpage>3811</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.5b00482</pub-id><pub-id pub-id-type="other">2-s2.0-84962038090</pub-id><?supplied-pmid 26935812?><pub-id pub-id-type="pmid">26935812</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surendra Kumar</surname><given-names>R.</given-names></name><name><surname>Moydeen</surname><given-names>M.</given-names></name><name><surname>Al-Deyab</surname><given-names>S. S.</given-names></name><name><surname>Aseer</surname><given-names>M.</given-names></name><name><surname>Idhayadhulla</surname><given-names>A.</given-names></name></person-group><article-title>Synthesis of new morpholine - connected pyrazolidine derivatives and their antimicrobial, antioxidant, and cytotoxic activities</article-title><source><italic toggle="yes">Bioorganic &#x00026; Medicinal Chemistry Letters</italic></source><year>2017</year><volume>27</volume><issue>1</issue><fpage>66</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2016.11.032</pub-id><pub-id pub-id-type="other">2-s2.0-84999015110</pub-id><?supplied-pmid 27889456?><pub-id pub-id-type="pmid">27889456</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li&#x000e9;geois</surname><given-names>C.</given-names></name><name><surname>Lermusieau</surname><given-names>G.</given-names></name><name><surname>Collin</surname><given-names>C.</given-names></name></person-group><article-title>Measuring Antioxidant Efficiency of Wort, Malt, and Hops against the 2,2&#x02018;-Azobis(2-amidinopropane) Dihydrochloride-Induced Oxidation of an Aqueous Dispersion of Linoleic Acid</article-title><source><italic toggle="yes">Journal of Agricultural and Food Chemistry</italic></source><year>2000</year><volume>48</volume><issue>4</issue><fpage>1129</fpage><lpage>1134</lpage><pub-id pub-id-type="doi">10.1021/jf9911242</pub-id><pub-id pub-id-type="other">2-s2.0-0343527423</pub-id><?supplied-pmid 10775361?><pub-id pub-id-type="pmid">10775361</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scudiero</surname><given-names>A. D.</given-names></name><name><surname>Shoemaker</surname><given-names>R. H.</given-names></name><name><surname>Paull</surname><given-names>K. D.</given-names></name></person-group><article-title>Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines</article-title><source><italic toggle="yes">Cancer Research</italic></source><year>1988</year><volume>48</volume><issue>17</issue><fpage>4827</fpage><lpage>4833</lpage><?supplied-pmid 3409223?><pub-id pub-id-type="pmid">3409223</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Biologically active natural pyrimidinamine compounds.</p></caption><graphic xlink:href="BMRI2020-8872479.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Structure of telmisartan.</p></caption><graphic xlink:href="BMRI2020-8872479.002"/></fig><fig id="sch1" orientation="portrait" position="float"><label>Scheme 1</label><caption><p>Synthetic route of 2-pyrimidinamine derivatives.</p></caption><graphic xlink:href="BMRI2020-8872479.sch.001"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>FT-IR spectrum for telmisartan-mediated copper nanoparticle.</p></caption><graphic xlink:href="BMRI2020-8872479.003"/></fig><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>UV-vis spectra of Cu-Nps.</p></caption><graphic xlink:href="BMRI2020-8872479.004"/></fig><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Telmisartan Cu-Nps of SEM images.</p></caption><graphic xlink:href="BMRI2020-8872479.005"/></fig><fig id="fig6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Telmisartan-copper nanoparticle of ED.</p></caption><graphic xlink:href="BMRI2020-8872479.006"/></fig><fig id="fig7" orientation="portrait" position="float"><label>Figure 7</label><caption><p>XRD studies of telmisartan-mediated copper nanoparticle.</p></caption><graphic xlink:href="BMRI2020-8872479.007"/></fig><fig id="fig8" orientation="portrait" position="float"><label>Figure 8</label><caption><p>(a) AFM image of Cu-Np catalyst. (b) The profile of Cu in telmisartan-mediated copper nanaoparicles. (c) The waviness of Cu-Nps. (d) The roughness of Cu-Nps.</p></caption><graphic xlink:href="BMRI2020-8872479.008"/></fig><fig id="fig9" orientation="portrait" position="float"><label>Figure 9</label><caption><p>TG/DTA curve of Cu-Np precursor.</p></caption><graphic xlink:href="BMRI2020-8872479.009"/></fig><fig id="fig10" orientation="portrait" position="float"><label>Figure 10</label><caption><p>Particle size analysis of Cu-Nps.</p></caption><graphic xlink:href="BMRI2020-8872479.010"/></fig><fig id="fig11" orientation="portrait" position="float"><label>Figure 11</label><caption><p>Recyclability of telmisartan copper nanoparticle catalyst.</p></caption><graphic xlink:href="BMRI2020-8872479.011"/></fig><fig id="sch2" orientation="portrait" position="float"><label>Scheme 2</label><caption><p>Catalysis performance with mechanism of compound preparation <bold>(</bold>1a-1c).</p></caption><graphic xlink:href="BMRI2020-8872479.sch.002"/></fig><fig id="sch3" orientation="portrait" position="float"><label>Scheme 3</label><caption><p>Mechanism of expected product and unreacted unexpected copper nanoparticles connected 2-pyrimidine compounds.</p></caption><graphic xlink:href="BMRI2020-8872479.sch.003"/></fig><fig id="sch4" orientation="portrait" position="float"><label>Scheme 4</label><caption><p>ABTS<sup>&#x000b7;+</sup> radical scavenging&#x02014;mechanism of inhibition.</p></caption><graphic xlink:href="BMRI2020-8872479.sch.004"/></fig><fig id="sch5" orientation="portrait" position="float"><label>Scheme 5</label><caption><p>Lipid peroxidation&#x02014;mechanism of inhibition.</p></caption><graphic xlink:href="BMRI2020-8872479.sch.005"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Antioxidant activities of pyrimidinamine derivatives 1a-c, Cu-N, and Cu-N-Pyr.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Compounds</th><th align="center" colspan="2" rowspan="1">Percentage of activity (%)<sup>a</sup></th></tr><tr><th align="center" rowspan="1" colspan="1">ABTS<sup>&#x000b7;<italic>+</italic></sup></th><th align="center" rowspan="1" colspan="1">AAPH</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1a</td><td align="center" rowspan="1" colspan="1">54.3 &#x000b1; 0.07</td><td align="center" rowspan="1" colspan="1">64.2 &#x000b1; 0.61</td></tr><tr><td align="left" rowspan="1" colspan="1">1b</td><td align="center" rowspan="1" colspan="1">61.0 &#x000b1; 0.12</td><td align="center" rowspan="1" colspan="1">72.0 &#x000b1; 0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">1c</td><td align="center" rowspan="1" colspan="1">80.8 &#x000b1; 0.12</td><td align="center" rowspan="1" colspan="1">71.6 &#x000b1; 0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">Cu-Nps</td><td align="center" rowspan="1" colspan="1">28.3 &#x000b1; 0.10</td><td align="center" rowspan="1" colspan="1">37.9 &#x000b1; 0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">Cu-Nps &#x02013;Pyr-1a</td><td align="center" rowspan="1" colspan="1">72.1 &#x000b1; 0.23</td><td align="center" rowspan="1" colspan="1">78.3 &#x000b1; 0.61</td></tr><tr><td align="left" rowspan="1" colspan="1">Cu-Nps &#x02013;Pyr-1b</td><td align="center" rowspan="1" colspan="1">86.3 &#x000b1; 0.13</td><td align="center" rowspan="1" colspan="1">80.3 &#x000b1; 0.42</td></tr><tr><td align="left" rowspan="1" colspan="1">Cu-Nps &#x02013;Pyr-1c</td><td align="center" rowspan="1" colspan="1">97.2 &#x000b1; 0.20</td><td align="center" rowspan="1" colspan="1">91.2 &#x000b1; 0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">Trolox</td><td align="center" rowspan="1" colspan="1">85.2 &#x000b1; 0.09</td><td align="center" rowspan="1" colspan="1">62.3 &#x000b1; 0.28</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>a</sup>Values are the meansofthreereplicates &#x000b1; SD.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>EDX analysis of percentage of elements present in Cu-Nps.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Element line</th><th align="center" rowspan="1" colspan="1">Weight (%)</th><th align="center" rowspan="1" colspan="1">Weight % error</th><th align="center" rowspan="1" colspan="1">Atom (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">C K</td><td align="center" rowspan="1" colspan="1">74.54</td><td align="center" rowspan="1" colspan="1">&#x000b1;3.03</td><td align="center" rowspan="1" colspan="1">82.93</td></tr><tr><td align="left" rowspan="1" colspan="1">O K</td><td align="center" rowspan="1" colspan="1">18.75</td><td align="center" rowspan="1" colspan="1">&#x000b1;2.92</td><td align="center" rowspan="1" colspan="1">15.66</td></tr><tr><td align="left" rowspan="1" colspan="1">Cu K</td><td align="center" rowspan="1" colspan="1">6.72</td><td align="center" rowspan="1" colspan="1">&#x000b1;3.54</td><td align="center" rowspan="1" colspan="1">1.41</td></tr><tr><td align="left" rowspan="1" colspan="1">Cu L</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">100.00</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">100.00</td></tr></tbody></table></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Catalyst recyclability.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Entry</th><th align="center" rowspan="1" colspan="1">Catalyst use</th><th align="center" rowspan="1" colspan="1">Yield (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1<sup>st</sup></td><td align="center" rowspan="1" colspan="1">88</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2<sup>nd</sup></td><td align="center" rowspan="1" colspan="1">88</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3<sup>rd</sup></td><td align="center" rowspan="1" colspan="1">88</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">4<sup>th</sup></td><td align="center" rowspan="1" colspan="1">88</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">5<sup>th</sup></td><td align="center" rowspan="1" colspan="1">88</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">6<sup>th</sup></td><td align="center" rowspan="1" colspan="1">87</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">7<sup>th</sup></td><td align="center" rowspan="1" colspan="1">87</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">8<sup>th</sup></td><td align="center" rowspan="1" colspan="1">86</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">9<sup>th</sup></td><td align="center" rowspan="1" colspan="1">86</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">10<sup>th</sup></td><td align="center" rowspan="1" colspan="1">85</td></tr></tbody></table></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Optimization of reaction condition.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">S. no.</th><th align="center" rowspan="1" colspan="1">R</th><th align="center" rowspan="1" colspan="1">Ar</th><th align="center" rowspan="1" colspan="1">Reaction condition</th><th align="center" rowspan="1" colspan="1">Catalyst mole (%)</th><th align="center" rowspan="1" colspan="1">Yield (%)</th><th align="center" rowspan="1" colspan="1">Final product structure</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1a</td><td align="center" rowspan="1" colspan="1">-NH<sub>2</sub></td><td align="center" rowspan="1" colspan="1">Ph</td><td align="center" rowspan="1" colspan="1">10&#x02009;min, RT</td><td align="center" rowspan="1" colspan="1">1.0</td><td align="center" rowspan="1" colspan="1">88</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="BMRI2020-8872479.tab4.i001.jpg"/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">1b</td><td align="center" rowspan="1" colspan="1">-NH-Ph</td><td align="center" rowspan="1" colspan="1">Ph</td><td align="center" rowspan="1" colspan="1">10&#x02009;min, RT</td><td align="center" rowspan="1" colspan="1">1.0</td><td align="center" rowspan="1" colspan="1">88</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="BMRI2020-8872479.tab4.i002.jpg"/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">1c</td><td align="center" rowspan="1" colspan="1">-CS-NH<sub>2</sub></td><td align="center" rowspan="1" colspan="1">Ph</td><td align="center" rowspan="1" colspan="1">10&#x02009;min, RT</td><td align="center" rowspan="1" colspan="1">1.0</td><td align="center" rowspan="1" colspan="1">88</td><td align="center" rowspan="1" colspan="1">
<inline-graphic xlink:href="BMRI2020-8872479.tab4.i003.jpg"/>
</td></tr></tbody></table></table-wrap><table-wrap id="tab5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Optimization of catalyst of Cu-Nps.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">S. No.</th><th align="center" rowspan="1" colspan="1">Catalyst</th><th align="center" rowspan="1" colspan="1">Mole (%)</th><th align="center" rowspan="1" colspan="1">Yield (%)</th><th align="center" rowspan="1" colspan="1">Yield (%) of Cu-N-Pyr</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Telmisartan</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">56</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Cu-Nps</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">94</td><td align="center" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">Cu-Nps</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">92</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Cu-Nps</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">Cu-Nps</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">Cu-Nps</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">88</td><td align="center" rowspan="1" colspan="1">12</td></tr></tbody></table></table-wrap><table-wrap id="tab6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Cytotoxic activities of pyrimidinamine derivatives 1a-c, Cu-N, and Cu-N-Pyr.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Compounds</th><th align="center" colspan="3" rowspan="1">HepG2</th><th align="center" colspan="3" rowspan="1">MCF-7</th><th align="center" colspan="3" rowspan="1">HeLa</th></tr><tr><th align="center" rowspan="1" colspan="1">GI<sub>50</sub> (<italic>&#x003bc;</italic>M)</th><th align="center" rowspan="1" colspan="1">TGI (<italic>&#x003bc;</italic>M)</th><th align="center" rowspan="1" colspan="1">LC<sub>50</sub> (<italic>&#x003bc;</italic>M)</th><th align="center" rowspan="1" colspan="1">GI<sub>50</sub> (<italic>&#x003bc;</italic>M)</th><th align="center" rowspan="1" colspan="1">TGI (<italic>&#x003bc;</italic>M)</th><th align="center" rowspan="1" colspan="1">LC<sub>50</sub> (<italic>&#x003bc;</italic>M)</th><th align="center" rowspan="1" colspan="1">GI<sub>50</sub> (<italic>&#x003bc;</italic>M)</th><th align="center" rowspan="1" colspan="1">TGI (<italic>&#x003bc;</italic>M)</th><th align="center" rowspan="1" colspan="1">LC<sub>50</sub> (<italic>&#x003bc;</italic>M)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1a</td><td align="center" rowspan="1" colspan="1">03.2</td><td align="center" rowspan="1" colspan="1">09.3</td><td align="center" rowspan="1" colspan="1">32.1</td><td align="center" rowspan="1" colspan="1">0.06</td><td align="center" rowspan="1" colspan="1">0.62</td><td align="center" rowspan="1" colspan="1">12.0</td><td align="center" rowspan="1" colspan="1">0.69</td><td align="center" rowspan="1" colspan="1">12.3</td><td align="center" rowspan="1" colspan="1">25.6</td></tr><tr><td align="left" rowspan="1" colspan="1">1b</td><td align="center" rowspan="1" colspan="1">02.1</td><td align="center" rowspan="1" colspan="1">06.1</td><td align="center" rowspan="1" colspan="1">24.1</td><td align="center" rowspan="1" colspan="1">12.2</td><td align="center" rowspan="1" colspan="1">24.3</td><td align="center" rowspan="1" colspan="1">42.2</td><td align="center" rowspan="1" colspan="1">0.09</td><td align="center" rowspan="1" colspan="1">20.3</td><td align="center" rowspan="1" colspan="1">41.2</td></tr><tr><td align="left" rowspan="1" colspan="1">1c</td><td align="center" rowspan="1" colspan="1">06.3</td><td align="center" rowspan="1" colspan="1">14.3</td><td align="center" rowspan="1" colspan="1">44.1</td><td align="center" rowspan="1" colspan="1">10.2</td><td align="center" rowspan="1" colspan="1">20.3</td><td align="center" rowspan="1" colspan="1">41.3</td><td align="center" rowspan="1" colspan="1">12.3</td><td align="center" rowspan="1" colspan="1">24.6</td><td align="center" rowspan="1" colspan="1">46.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Cu-Nps</td><td align="center" rowspan="1" colspan="1">12.3</td><td align="center" rowspan="1" colspan="1">24.2</td><td align="center" rowspan="1" colspan="1">45.3</td><td align="center" rowspan="1" colspan="1">18.5</td><td align="center" rowspan="1" colspan="1">36.2</td><td align="center" rowspan="1" colspan="1">69.6</td><td align="center" rowspan="1" colspan="1">21.0</td><td align="center" rowspan="1" colspan="1">46.3</td><td align="center" rowspan="1" colspan="1">84.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Cu-Nps-Pyr-1a</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">0.21</td><td align="center" rowspan="1" colspan="1">0.59</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">0.28</td><td align="center" rowspan="1" colspan="1">0.81</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">0.19</td><td align="center" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" rowspan="1" colspan="1">Cu-Nps-Pyr-1b</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">06.1</td><td align="center" rowspan="1" colspan="1">24.1</td><td align="center" rowspan="1" colspan="1">12.2</td><td align="center" rowspan="1" colspan="1">24.3</td><td align="center" rowspan="1" colspan="1">42.2</td><td align="center" rowspan="1" colspan="1">0.12</td><td align="center" rowspan="1" colspan="1">0.33</td><td align="center" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" rowspan="1" colspan="1">Cu-Nps-Pyr-1c</td><td align="center" rowspan="1" colspan="1">0.05</td><td align="center" rowspan="1" colspan="1">14.3</td><td align="center" rowspan="1" colspan="1">44.1</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">0.13</td><td align="center" rowspan="1" colspan="1">0.53</td><td align="center" rowspan="1" colspan="1">0.05</td><td align="center" rowspan="1" colspan="1">0.16</td><td align="center" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" rowspan="1" colspan="1">Doxorubicin</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">0.13</td><td align="center" rowspan="1" colspan="1">0.58</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">0.21</td><td align="center" rowspan="1" colspan="1">0.74</td><td align="center" rowspan="1" colspan="1">0.05</td><td align="center" rowspan="1" colspan="1">0.41</td><td align="center" rowspan="1" colspan="1">0.88</td></tr></tbody></table></table-wrap></floats-group></article>